Research & Development
Grifols awarded US FDA approval for scalable blood typing solution Erytra Eflexis
9 January 2019 -

Transfusion medicine company Grifols revealed on Tuesday the receipt of approval from the US Food and Drug Administration approval for Erytra Eflexis, a fully automated, benchtop blood typing analyzer.

Following the US FDA approval, Erytra Eflexis expands the company's portfolio of blood typing solutions and can be used as a stand-alone system or in combination with other Grifols blood typing portfolio solutions.

Grifols added that the Erytra Eflexis system performs pretransfusion compatibility testing using DG Gel technology. It incorporates two lab configurations in a single instrument so laboratories can select the solution best suited to various workflow needs and capacities. The Interchangeable sample and reagent linear racks allow easy, continuous loading of cards, reagents and samples.

According to the company, Erytra Eflexis features real random access with a capacity of up to 200 cards, 72 samples and 46 liquid reagents. The transparent casing provides a clear view of the simple internal organisation and processes.

This smart, flexible and intuitive system optimises workflow efficiency and improves daily workloads, providing laboratories with a high level of flexibility and adaptability. It is designed for enhanced quality control to support improved patient care, concluded the company.